血管腔内时代1000例腹主动脉瘤修复结局分析
该回顾性队列研究分析了1998年至2014年间1000例腹主动脉瘤修复患者,其中开放手术占68.1%,腔内修复占31.9%。结果显示两种方式中期生存良好,EVAR可降低73.5岁以上患者早期死亡率,但73.5岁以下低中危患者EVAR无优势。
要点
- EVAR组早期死亡率低于开放手术组(0.3% vs 1.9%,P=0.046)。
- 73.5岁以下患者开放手术与EVAR死亡率无差异(P=0.996)。
- 开放手术组再干预率更低(HR 1.93,95%CI 1.27-2.93,P=0.002)。
核心结论
- 择期腹主动脉瘤修复无论开放手术或EVAR均提供良好的中期结局。
- EVAR降低73.5岁以上患者早期死亡率;73.5岁以下低中危患者EVAR无优势,不应作为首选。
研究设计与样本
- 回顾性队列研究,纳入1998年1月至2014年11月间1000例腹主动脉瘤修复患者,开放手术占68.1%,EVAR占31.9%。
主要发现
- EVAR组吸烟者33.2% vs 21%(P<0.001),高胆固醇血症56.4% vs 41.1%(P<0.001),1型糖尿病11.3% vs 2.8%(P<0.001),缺血性心脏病36.4% vs 25.0%(P=0.013),慢性肾功能衰竭25.4% vs 16.2%(P<0.001),年龄74.6±7.1 vs 68.3±7.2岁(P<0.001)。
- 开放手术组下肢慢性缺血22.8% vs 9.4%(P<0.001),动脉瘤直径61.2±13.6 vs 58.5±13.8 mm(P<0.001),瘤颈直径24.1±3.9 vs 23.3±3.0 mm(P=0.002),瘤颈长度15.1±11.1 vs 24.0±11.1 mm(P<0.001)。
- 早期死亡率开放手术1.9% vs EVAR 0.3%(P=0.046);开放手术和年龄是早期死亡独立预测因素(OR 16.98,95%CI 1.97-146.29,P<0.001;OR 1.22,95%CI 1.09-1.36,P<0.001)。
- 开放手术组术后并发症更多(23.9% vs 9.7%,P<0.001),早期再干预更多(4.4% vs 1.6%,P=0.026);EVAR组肾功能损害更常见(6.6% vs 3.5%,P=0.034),但多因素分析无统计学意义(OR 0.84,95%CI 0.41-1.69,P=0.618)。
- 随访中位时间EVAR组33个月(范围0-175),开放手术组59个月(范围0-190);24和48个月生存率EVAR 92.9%和83.9%,开放手术94.6%和90.6%(P<0.001),多因素分析无统计学意义(HR 1.46,95%CI 0.99-2.12,P=0.060)。
关键数值与推荐
- 年龄(HR 1.09,95%CI 1.06-1.11,P<0.001)、慢性阻塞性肺疾病(HR 1.39,95%CI 1.04-1.86,P=0.026)和慢性肾功能衰竭(HR 2.08,95%CI 1.51-2.87,P<0.001)与更差生存独立相关。
临床怎么用
- 对于73.5岁以上患者,EVAR可降低早期死亡率,应优先考虑。
- 73.5岁以下低中危患者,开放手术在再干预方面可能更优,EVAR不应作为首选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To analyze the outcome of abdominal aortic aneurysm (AAA) repair with elective open surgery (OS) versus endovascular aneurysm repair (EVAR) and assess the predictors of survival. METHODS: A retrospective cohort study was made of 1000 AAA treated between January 1998 and November 2014 (68.1% OS and 31.9% EVAR), with the comparison of comorbidity and complications, and survival analysis (Kaplan-Meier and Breslow). Multivariate logistic regression and Cox regression analyses were performed. RESULTS: The EVAR group had a higher prevalence of smokers (33.2% vs. 21%; P < 0.001), hypercholesterolemia (56.4% vs. 41.1%; P < 0.001), type 1 diabetes (11.3% vs. 2.8%; P < 0.001), ischemic heart disease (36.4% vs. 25.0%; P = 0.013), chronic renal failure (25.4% vs. 16.2%; P < 0.001), and an older age [74.6 ± 7.1 vs. 68.3 ± 7.2 (years); P < 0.001]. The OS group showed a greater prevalence of chronic ischemia of the lower extremities (22.8% vs. 9.4%; P < 0.001), a greater AAA diameter [61.2 ± 13.6 vs. 58.5 ± 13.8 (mm); P < 0.001], a greater aneurysm neck diameter [24.1 ± 3.9 vs. 23.3 ± 3.0 (mm); P = 0.002], and a shorter aneurysm neck length [15.1 ± 11.1 vs. 24.0 ± 11.1 (mm); P < 0.001]. Early mortality was low in both groups but higher with OS (1.9% vs. 0.3%; P = 0.046). OS [OR 16.98 (95% CI: 1.97-146.29) (P < 0.001)] and age [OR 1.22 (95% CI: 1.09-1.36) (P < 0.001)] were independent predictors of higher early mortality. However, there was no increase in mortality in the OS group in patients under 73.5 years (P = 0.996), and the differences increased over 73.5 years of age (P = 0.005). There were also more postoperative complications (23.9% vs. 9.7%; P < 0.001) and early reinterventions in the OS group (4.4% vs. 1.6%; P = 0.026). Only the prevalence of renal function impairment was greater in the EVAR group (6.6% vs. 3.5%; P = 0.034), but this complication resulted not significative in the multivariate analysis [OR 0.84 (95% CI: 0.41-1.69) (P = 0.618)]. The median duration of follow-up was 33 (range 0-175) and 59 months (range 0-190) for the EVAR and OS groups, respectively. The survival rate after 24 and 48 months was 92.9% and 83.9% (EVAR) versus 94.6% and 90.6% (OS) (P < 0.001). This difference was not significative in the multivariable analysis: hazard ratio (HR) 1.46 (95% CI 0.99 to 2.12); P = 0.060. OS also resulted in better freedom from reintervention rates for the same periods: 92.1% and 90.4% versus 92.9% and 88.1%, including multivariate analysis [HR 1.93 (95% CI 1.27 to 2.93) P = 0.002]. The factors independently associated to poorer survival were age [HR 1.09 (1.06-1.11); P < 0.001], chronic obstructive pulmonary disease [HR 1.39 (1.04-1.86); P = 0.026], and chronic renal failure [HR 2.08 (1.51-2.87); P < 0.001]. CONCLUSIONS: Elective AAA repair offers excellent middle-term outcomes with both OS and EVAR. EVAR reduces early mortality in the subgroup of patients older than 73.5 years. In patients younger than 73.5 years with a low to moderate surgical risk, EVAR offers no advantage over OS and therefore should not be regarded as the treatment of choice.
引用
- Revuelta Suero S, Martínez López I, Hernández Mateo M, et al. Outcomes of the Repair of 1000 Abdominal Aortic Aneurysms in the Endovascular Era. Ann Vasc Surg. 2019. PMID: 30802567. doi:10.1016/j.avsg.2018.12.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。